References
- 1. T. I. Oprea and J. Mestres, Drug repurposing: Far beyond new targets for old drugs, AAPS J.14 (2012) 759–763.
- 2. T. T. Ashburn and K. B. Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov.3 (2004) 673–683; https://doi.org/10.1038/nrd1468
- 3. V. R. Solomon and H. Lee, Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies, Eur. J. Pharmacol.625 (2009) 220–233; https://doi.org/10.1016/j.ejphar.2009.06.063
- 4. R. Duffy, C. Wade and R. Chang, Discovery of anticancer drugs from antimalarial natural products: a MEDLINE literature review, Drug Discov. Today17 (2012) 942–953.; https://doi.org/10.1016/j.drudis.2012.03.013
- 5. T. Kimura, Y. Takabatake, A. Takahashi and Y. Isaka, Chloroquine in cancer therapy: A double-edged sword of autophagy, Cancer Res.73 (2013) 3–7; https://doi.org/10.1158/0008-5472
- 6. R. H. van Huijsduijnen, R. Kiplin Guy, K. Chibale, R. K. Haynes, I. Peitz, G. Kelter, M. A. Phillips, J. L. Vennerstrom, Y. Yuthavong and T. N. C. Wells, Anticancer properties of distinct antimalarial drug classes, PLoS One8 (2013) e82962.
- 7. A. K. Abdel-Aziz, S. Shouman, E. El-Demerdash, M. Elgendy and A. B. Abdel-Naim, Chloroquine as a promising adjuvant chemotherapy together with sunitinib, Sci. Proc.1 (2014) Article ID e384; https://doi.org/10.14800/sp.384
- 8. F. Liu, Y. Shang and S.-Z. Chen, Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro, Acta Pharmacol. Sin. 35 (2014) 645–652; https://doi.org/10.1038/aps.2014.3
- 9. A. R. Choi, J. H. Kim, Y. H. Woo, H. S. Kim and S. Yoon, Anti-malarial drugs primaquine and chloroquine have different sensitization effects with anti-mitotic drugs in resistant cancer cells, Anticancer Res. 36 (2016) 1641–1648.
- 10. A. Ganguli, D. Choudhury, S. Datta, S. Bhattacharya and G. Chakrabarti, Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis, Biochimie107 (2014) 338–349; https://doi.org/10.1016/j.biochi.2014.10.001
- 11. C. Verbaanderd, H. Maes, M. B. Schaaf, V. P. Sukhatme, P. Pantziarka, V. Sukhatme, P. Agostinis and G. Bouche, Repurposing drugs in oncology (ReDO) – chloroquine and hydroxychloroquine as anti-cancer agents, eCancer11 (2017) Article ID 781; https://doi.org/10.3332/ecancer.2017.781
- 12. F. Wang, J. Tang, P. Li, S. Si, H. Yu, X. Yang, J. Tao, Q. Lv, M. Gu, H. Yang and Z. Wang, Chloroquine enhances the radiosensitivity of bladder cancer cells by inhibiting autophagy and activating apoptosis, Cell. Physiol. Biochem.45 (2018) 54–66; https://doi.org/10.1159/000486222
- 13. L. Liu, C. Han, H. Yu, W. Zhu, H. Cui, L. Zheng, C. Zhang and L. Yue, Chloroquine inhibits cell growth in human A549 lung cancer cells by blocking autophagy and inducing mitochondrial-mediated apoptosis, Oncol. Rep.39 (2018) 2807–2816.
- 14. A. Kamal A. Aziz, S. Shouman, E. El-Demerdash, M. Elgendy and A. B. Abdel-Naim, Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries, Chem. Biol. Interact.217 (2014) 28–40; https://doi.org/10.1016/j.cbi.2014.04.007
- 15. G. W. Soo, J. H. Law, E. Kan, S. Y. Tan, W. Y. Lim, G. Chay, N. I. Bukhari and I. Segarra, Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice, Anticancer Drugs21 (2010) 695–703.
- 16. Y. K. Wong, C. Xu, K. A. Kalesh, Y. He, Q. Lin, W. S. F. Wong, H. M. Shen and J. Wang, Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action, Med. Res. Rev.37 (2017) 1492–1517.
- 17. https://clinicaltrials.gov/ct2/home (last access May 26, 2019)
- 18. https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines (last access May 27, 2019)
- 19. N. Vale, R. Moreira and P. Gomes, Primaquine revisited six decades after its discovery, Eur. J. Med. Chem.44 (2009) 937–953; https://doi.org/10.1016/j.ejmech.2008.08.011
- 20. P. M. Njaria, J. Okombo, N. M. Njuguna and K. Chibale, Chloroquine-containing compounds: a patent review (2010 – 2014), Expert Opin. Therap. Patents25 (2015) 1003–1024; https://doi.org/10.1517/13543776.2015.1050791
- 21. S-J. Yeo, D-X. Liu, H-S. Kim and H. Park, Anti-malarial effect of novel chloroquine derivatives as agents for the treatment of malaria, Malaria J.16 (2017) 80; https://doi.org/10.1186/s12936-017-1725-z
- 22. M. A. Avery, D. J. Weldon and K. M. Muraleedharan, Advances in the Discovery of New Antimalarials, in Comprehensive Medicinal Chemistry II (Eds. J. B. Taylor and D. J. Triggle), Vol. 7, Elsevier Ltd., 2007, pp. 765–814; https://doi.org/10.1016/B0-08-045044-X/00227-3
- 23. K. Pavić, Z. Rajić, Z. Mlinarić, L. Uzelac, M. Kralj and B. Zorc, Chloroquine urea derivatives: synthesis and antitumor activity in vitro, Acta Pharm. 68 (2018) 471–483.
- 24. M. Beus, L. Persoons, D. Schols, L. Uzelac, M. Kralj, Z. Rajić and B. Zorc, Cytotoxicity studies of primaquine and chloroquine fumardiamides, 6th Croatian Congress on Pharmacy with International Participation, Book of Abstract, PO-16, Dubrovnik, April 4–6, 2019
- 25. M. Beus, D. Fontinha, J. Held, Z. Rajić, M. Prudêncio and B. Zorc, Synthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides, Acta Pharm. 69 (2019) 233–248; https://doi.org/10.2478/acph-2019-0019
- 26. G. Džimbeg, B. Zorc, M. Kralj, K. Ester, K. Pavelić, J. Balzarini, E. De Clercq and M. Mintas, The novel primaquine derivatives of N-alkyl, cycloalkyl or aryl urea: synthesis, cytostatic and antiviral activity evaluations, Eur. J. Med. Chem.43 (2008) 1180–1187; https://doi.org/10.1016/j.ejmech.2007.09.001
- 27. M. Šimunović, I. Perković, B. Zorc, K. Ester, M. Kralj, D. Hadjipavlou-Litina and E. Pontiki, Urea and carbamate derivatives of primaquine: synthesis, cytostatic and antioxidant activities, Bioorg. Med. Chem.17 (2009) 5605–5613; https://doi.org/10.1016/j.bmc.2009.06.030
- 28. I. Perković, S. Tršinar, J. Žanetić, M. Kralj, I. Martin-Kleiner, J. Balzarini, D. Hadjipavlou-Litina and A. M. Katsori, Novel 1-acyl-4-substituted semicarbazide derivatives of primaquine – synthesis, cytostatic, antiviral and antioxidative studies, J. Enzyme Inhib. Med. Chem.28 (2013) 601–610; https://doi.org/10.3109/14756366.2012.663366
- 29. K. Pavić, I. Perković, M. Cindrić, M. Pranjić, I. Martin-Kleiner, M. Kralj, D. Schols, D. Hadjipavlou-Litina, A.-M. Katsori and B. Zorc, Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity, Eur. J. Med. Chem.86 (2014) 502–514; https://doi.org/10.1016/j.ejmech.2014.09.013
- 30. I. Perković, M. Antunović, I. Marijanović, K. Pavić, K. Ester, M. Kralj, J. Vlainić, I. Kosalec, D. Schols, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Novel urea and bis-urea primaquine derivatives with hydroxyphenyl and halogenphenyl substituents: synthesis and biological evaluation, Eur. J. Med. Chem.124 (2016) 622–636; https://doi.org/10.1016/j.ejmech.2016.08.021
- 31. K. Pavić, I. Perković, P. Gilja, F. Kozlina, K. Ester, M. Kralj, D. Schols, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Design, synthesis and biological evaluation of novel primaquine-cinnamic acid conjugates of amide and acylsemicarbazide type, Molecules21 (2016) 1629–1653; https://doi.org/10.3390/molecules21121629
- 32. K. Pavić, I. Perković, Š. Pospíšilová, M. Machado, D. Fontinha, M. Prudêncio, J. Jampilek, A. Coffey, L. Endersen, H. Rimac and B. Zorc, Primaquine hybrids as promising antimycobacterial and antimalarial agents, Eur. J. Med. Chem.143 (2018) 769–779; https://doi.org/10.1016/j.ejmech.2017.11.083
- 33. J. Vlainić, I. Kosalec, K. Pavić, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Insights into biological activity of ureidoamides with primaquine and amino acid moieties, J. Enzyme Inhib. Med. Chem.33 (2018) 376–382; https://doi.org/10.1080/14756366.2017.1423067
- 34. J. Levatić, K. Pavić, I. Perković, L. Uzelac, K. Ester, M. Kralj, M. Kaiser, M. Rottmann, F. Supek and B. Zorc, Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity, Eur. J. Med. Chem.146 (2018) 651–667; https://doi.org/10.1016/j.ejmech.2018.01.062
- 35. M. Beus, Z. Rajić, D. Maysinger, Z. Mlinarić, M. Antunović, I. Marijanović, D. Fontinha, M. Prudêncio, J. Held, S. Olgen and B. Zorc, SAHAquines, novel hybrids based on SAHA and primaquine motifs, as potential anticancer and antiplasmodial agents, ChemistryOpen7 (2018) 624–638; https://doi.org/10.1002/open.201800117
- 36. Z. Rajić, M. Beus, H. Michnova, J. Vlainić, L. Persoons, I. Kosalec, J. Jampilek, D. Schols, T. Keser and B. Zorc, Asymmetric primaquine and halogenaniline fumardiamides as novel biologically active Michael acceptors, Molecules23 (2018) 1724; https://doi.org/10.3390/molecules23071724
- 37. I. Zhang, M. Beus, U. Stochaj, P. U. Le, B. Zorc, Z. Rajić, K. Petrecca and D. Maysinger, Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule, Cell Death Discov. 5 (2019) 41; https://doi.org/10.1038/s41420-018-0103-0
- 38. K. Pavić, Z. Rajić, H. Michnová, J. Jampílek, I. Perković and B. Zorc, Second generation of primaquine ureas and bis-ureas as potential antimycobacterial agents, Mol. Diver. (2018); https://doi.org/10.1007/s11030-018-9899-z
- 39. M. E. Flanagan, J. A. Abramite, D. P. Anderson, A. Aulabaugh, U. P. Dahal, A. M. Gilbert, C. Li, J. Montgomery, S. R. Oppenheimer, T. Ryder, B. P. Schuff, D. P. Uccello, G. S. Walker, Y. Wu, M. F. Brown, J. M. Chen, M. M. Hayward, M. C. Noe, R. S. Obach, L. Philippe, V. Shanmugasundaram, M. J. Shapiro, J. Starr, J. Stroh and Y. Che, Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors, J. Med. Chem.57 (2014) 10072–10079; https://doi.org/10.1021/jm501412a
- 40. I. Fernandes, N. Vale, V. de Freitas, R. Moreira, N. Mateus and P. Gomes, Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine, Bioorg. Med. Chem. Lett.19 (2009) 6914–6917; https://doi.org/10.1016/j.bmcl.2009.10.081
- 41. T. Rossi, A. Coppi, E. Bruni, A. Ruberto, S. Santachiara and G. A. Baggio, Effects of anti-malarial drugs on MCF-7 and Vero cell replication, Anticancer Res. 27 (2007) 2555–2559.
- 42. A. R. Martirosyan, R. Rahim-Bata, A. B. Freeman, C. D. Clarke, R. L. Howard and J. S. Strobl, Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model, Biochem. Pharmacol. 68 (2004) 1729–1738.